| Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥11,830,000 (Direct Cost: ¥9,100,000、Indirect Cost: ¥2,730,000)
|
|---|
| Outline of Final Research Achievements |
Firstly, we constructed the plasmid vector which included Slc26a4 gene targeted short hairpin RNA with tet system. Then, that plasmid vector was injected and transferred into otocyst at embryonic day 11.5 according to our previous reported methods.
Doxycycline was administrated via ingestion between embryonic day 16 to postnatal day 6. As control, no Doxycycline group were used. Auditory assessment showed that hearing loss was detected in the treated mice, but not in the non-treated mice at postnatal day 30. Our results suggested that Slc26a4 gene expression between embryonic day 16 to postnatal day 6 was crucial for hearing. In the future, we investigate the Slc26a4 gene expression timing which is necessary for hearing.
|
